Passage BIO, Inc.
PASG Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$3.35
KIRA · Stoqly’s AI analyst, in plain words
- Passage BIO, Inc. lost $45.5M in fiscal 2025.
Market cap
$10.7M
P/E
—
Revenue
—
Net income
−$45.5M
Free cash flow
—
Operating margin
—
Passage BIO, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$45.5M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Passage BIO, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Passage BIO, Inc.
- CIK
- 0001787297
Passage BIO, Inc. · PASG
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$185M | −$136M | −$102M | −$64.8M | −$45.5M |
| Diluted EPS | −$3.48 | −$2.50 | −$1.86 | −$21.04 | −$14.35 |
| Cash | |||||
| Cash from operations | −$127M | −$118M | −$78.3M | −$48.0M | −$31.5M |
| Capital expenditure | — | — | — | $0.0M | — |
| Free cash flow | — | — | — | −$48.0M | — |
| Share count change | 38.1% | 2.0% | 0.6% | −94.4% | 3.1% |
| Debt and strength | |||||
| Cash and short-term investments | $316M | $190M | $114M | $76.8M | $46.3M |
| Shareholders' equity | $319M | $201M | $111M | $61.3M | $18.8M |
| Current ratio | 11.0x | 10.7x | 7.2x | 4.1x | 2.1x |
| Returns and quality | |||||
| Return on equity | −59.5% | −52.4% | −65.3% | −75.1% | −113.8% |
| Return on tangible equity | −58.2% | −67.6% | −91.7% | −105.7% | −242.7% |
| Altman Z'' | 7.9 | −0.6 | −10.3 | −20.2 | −39.2 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$0.1M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Passage BIO, Inc. · PASG
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.35 a share, the company is worth $10.7M.
Source: SEC EDGAR XBRL filings (CIK 0001787297). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.